The Worldwide Healthcare Third-party Logistics Industry is Expected to Reach $368 Million by 2030

2022-10-17
疫苗
DUBLIN, Oct. 17, 2022 /PRNewswire/ -- The "Healthcare Third-party Logistics Market Size, Share & Trends Analysis Report by Industry (Biopharmaceutical, Pharmaceutical, Medical Device), by Supply Chain, by Service Type, by Region, and Segment Forecasts, 2022-2030" report has been added to
ResearchAndMarkets.com's offering.
The global healthcare third-party logistics market size is expected to reach USD 368.2 million by 2030, according to this report. The market is anticipated to expand at a CAGR of 7.6% from 2022 to 2030.
A few factors driving the growth of this market are technological advancements that help in developing new technologies to engage with consumers, help in the reduction of operational costs, and help in expanding the business into emerging countries and new markets.
The COVID-19 pandemic significantly impacted the supply chain market and the way it is managed. However, the third-party logistics industry showed growth amid this pandemic.
This is because they matched the rising demand with reliable manufacturers worldwide. In addition to the basic storage and transportation services during the pandemic, they also provided procurement assistance to relatively small retailers.
For instance, in September 2021, FedEx Corp. subsidiary FedEx Express delivered COVID-19 swab kits and personal protective equipment on 15 pallets to Jakarta, Indonesia.
There has also been an increase in healthcare companies partnering with third-party logistics providers to operate in a growing and changing set of regulatory requirements that vary by product classification, region, and state.
Healthcare third-party logistics (3PL) help in complying with these regulations without disturbing the time duration, efficiency, and cost-effectiveness. They also help in streamlining and simplifying the regulatory compliance process.
Healthcare Third-party Logistics Market Report Highlights
The industry segment is segmented into biopharmaceutical, pharmaceutical, and medical devices. And the biopharmaceutical segment accounted for the largest revenue share of 62.6% in 2021
The cold chain logistics segment is anticipated to advance at the fastest CAGR of 10.5% during the forecast period. This is due to the rising demand for biologics which is a novel class of pharmaceutical
North America dominated the global market with the largest revenue share of 42.0% in 2021 owing to the presence of a large number of players as well as growth in pharmaceutical and biopharmaceutical exports and imports
For instance, in April 2021, FedEx Corp. subsidiary FedEx Express supplied 1,000 oxygen cylinders and 1,800 pounds of personal protective equipment and medicines to India
Key Topics Covered:
Chapter 1. Methodology and Scope
Chapter 3. Healthcare Third Party Logistics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.3.3. Penetration & Growth Prospect Mapping
3.3.4. COVID Impact Analysis
3.3.5. Major Deals and Strategic Alliances Analysis
3.3.6. Industry Analysis - Porter's
3.3.7. Pestle Analysis
Chapter 4. Healthcare Third Party Logistics Market: Industry Segment Analysis
4.1. Healthcare Third Party Logistics Market: Definition & Scope
4.2. Healthcare Third Party Logistics Market: Industry Market Share Analysis, 2021 & 2030
4.2.1.1. Biopharmaceuticals Market, 2018 - 2030 (USD Million)
4.2.1.1.1. Vaccines
4.2.1.1.1.1. Vaccines Market, 2018 - 2030 (USD Million)
4.2.1.1.2. Plasma Derived Products
4.2.1.1.2.1. Plasma Derived Products Market, 2018 - 2030 (USD Million)
4.2.1.1.3. Others
4.2.1.1.3.1. Others Market, 2018 - 2030 (USD Million)
4.2.2. Medical Devices
4.2.2.1. Medical Devices Market, 2018 - 2030 (USD Million)
4.2.2.1.1. Class I
4.2.2.1.1.1. Class I Market, 2018 - 2030 (USD Million)
4.2.2.1.2. Class II
4.2.2.1.2.1. Class II Market, 2018 - 2030 (USD Million)
4.2.2.1.3. Class III
4.2.2.1.3.1. Class III Market, 2018 - 2030 (USD Million)
4.2.3. Others
4.2.3.1. Others Market, 2018 - 2030 (USD Million)
Chapter 5. Healthcare Third Party Logistics Market: Service Type Segment Analysis
5.1. Healthcare Third Party Logistics Market: Definition & Scope
5.2. Healthcare Third Party Logistics Market: Service Type Market Share Analysis, 2021 & 2030
5.2.1. Transportation
5.2.1.1. Transportation Market, 2018 - 2030 (USD Million)
5.2.1.1.1. Air freight
5.2.1.1.1.1. Air freight Market, 2018 - 2030 (USD Million)
5.2.1.1.2. Sea freight
5.2.1.1.2.1. Sea freight Market, 2018 - 2030 (USD Million)
5.2.1.1.3.1. Overland Transportation Market, 2018 - 2030 (USD Million)
5.2.2. Warehousing and storage
5.2.2.1. Warehousing & storage Market, 2018 - 2030 (USD Million)
5.2.3. Others
5.2.3.1. Others Market, 2018 - 2030 (USD Million)
Chapter 6. Healthcare Third Party Logistics Market: Supply Chain Segment Analysis
6.1. Healthcare Third Party Logistics Market: Definition & Scope
6.2. Healthcare Third Party Logistics Market: Supply Chain Market Share Analysis, 2021 & 2030
6.2.1. Cold Chain
6.2.1.1. Cold Chain Market, 2018 - 2030 (USD Million)
6.2.2. Non-Cold Chain
6.2.2.1. Non-Cold Chain Market, 2018 - 2030 (USD Million)
Chapter 7. Healthcare Third Party Logistics Market: Regional Analysis
8.1. Company Profiles
8.1.1. FedEx
8.1.1.1. Company overview
8.1.1.2. Financial performance
8.1.1.3. Service benchmarking
8.1.1.4. Strategic initiatives
8.1.2.1. Company overview
8.1.2.2. Financial performance
8.1.2.3. Service benchmarking
8.1.2.4. Strategic initiatives
8.1.3. SF Express
8.1.3.1. Company overview
8.1.3.2. Financial performance
8.1.3.3. Service benchmarking
8.1.3.4. Strategic initiatives
8.1.4.1. Company overview
8.1.4.2. Financial performance
8.1.4.3. Service benchmarking
8.1.4.4. Strategic initiatives
8.1.5. Amerisource Bergen Corporation
8.1.5.1. Company overview
8.1.5.2. Financial performance
8.1.5.3. Service benchmarking
8.1.5.4. Strategic initiatives
8.1.6. DB Schenker
8.1.6.1. Company overview
8.1.6.2. Financial performance
8.1.6.3. Service benchmarking
8.1.6.4. Strategic initiatives
8.1.7. KUEHNE + NAGEL
8.1.7.1. Company overview
8.1.7.2. Financial performance
8.1.7.3. Service benchmarking
8.1.7.4. Strategic initiatives
8.1.8.1. Company overview
8.1.8.2. Financial performance
8.1.8.3. Service benchmarking
8.1.8.4. Strategic initiatives
8.1.9. Agility
8.1.9.1. Company overview
8.1.9.2. Financial performance
8.1.9.3. Service benchmarking
8.1.9.4. Strategic initiatives
8.1.10. Kinesis Medical B.V.
8.1.10.1. Company overview
8.1.10.2. Financial performance
8.1.10.3. Service benchmarking
8.1.10.4. Strategic initiatives
8.1.11.1. Company overview
8.1.11.2. Financial performance
8.1.11.3. Service benchmarking
8.1.11.4. Strategic initiatives
8.1.12.1. Company overview
8.1.12.2. Financial performance
8.1.12.3. Service benchmarking
8.1.12.4. Strategic initiatives
8.1.13.1. Company overview
8.1.13.2. Financial performance
8.1.13.3. Service benchmarking
8.1.13.4. Strategic initiatives
For more information about this report visit https://www.researchandmarkets.com/r/hztrgh
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
靶点
-
药物
-
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。